A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+
              PIK3CA
              -mutated breast cancer

Jose Alejandro Pérez-Fidalgo; Carmen Criscitiello; Eva Carrasco; Meredith M Regan; Angelo Di Leo; Karin Ribi; Virginie Adam; Philippe L Bedard

doi:10.2217/fon-2022-0045

A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA -mutated breast cancer

Jose Alejandro Pérez-Fidalgo
, Carmen Criscitiello
, Eva Carrasco
, Meredith M Regan
, Angelo Di Leo
, Karin Ribi
, Virginie Adam
, Philippe L Bedard

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

Originalsprache	Englisch
Seiten (von - bis)	2339-2349
Fachzeitschrift	Future Oncology
Jahrgang	18
Ausgabenummer	19
DOIs	https://doi.org/10.2217/fon-2022-0045
Publikationsstatus	Veröffentlicht - 1 Juni 2022
Extern publiziert	Ja

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Zugriff auf Dokument

10.2217/fon-2022-0045

https://www.tandfonline.com/doi/full/10.2217/fon-2022-0045

Dieses zitieren

@article{cd8617f5f97e4aada8e91b94b858d208,

title = "A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA -mutated breast cancer",

author = "P{\'e}rez-Fidalgo, \{Jose Alejandro\} and Carmen Criscitiello and Eva Carrasco and Regan, \{Meredith M\} and \{Di Leo\}, Angelo and Karin Ribi and Virginie Adam and Bedard, \{Philippe L\}",

year = "2022",

month = jun,

day = "1",

doi = "10.2217/fon-2022-0045",

language = "English",

volume = "18",

pages = "2339--2349",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Taylor and Francis Ltd.",

number = "19",

}

A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA -mutated breast cancer. / Pérez-Fidalgo, Jose Alejandro; Criscitiello, Carmen; Carrasco, Eva et al.
in: Future Oncology, Jahrgang 18, Nr. 19, 01.06.2022, S. 2339-2349.

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

TY - JOUR

T1 - A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA -mutated breast cancer

AU - Pérez-Fidalgo, Jose Alejandro

AU - Criscitiello, Carmen

AU - Carrasco, Eva

AU - Regan, Meredith M

AU - Di Leo, Angelo

AU - Ribi, Karin

AU - Adam, Virginie

AU - Bedard, Philippe L

PY - 2022/6/1

Y1 - 2022/6/1

U2 - 10.2217/fon-2022-0045

DO - 10.2217/fon-2022-0045

M3 - Article

SN - 1479-6694

VL - 18

SP - 2339

EP - 2349

JO - Future Oncology

JF - Future Oncology

IS - 19

ER -